

Faculty Disclosures

In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, course directors, planners, moderators, faculty, and all others in control of the educational content of the continuing education activity must disclose all financial relationships with ineligible companies that they may have had within the past 24 months. If an individual refuses to disclose financial relationships, they will be disqualified from being a part of the planning and implementation of the activity. Owners and/or employees of an ineligible company with business lines or products relating to the content of the activity will not be permitted to participate in the planning or execution of any accredited program. All listed relevant financial relationships with ineligible companies for individuals in control of content have been mitigated.

Name	Role	Ineligible Company	Nature of Relevant Financial Relationship
Alain Algazi, MD (UCSF)	Speaker	<ul style="list-style-type: none"> OncoSec, Valitor Biosciences, Regeneron, Array, Acerta, Amgen, AstraZeneca, BMS, Dynavax, Genentech, Idera, Incyte, ISA, Loxo Oncology, Merck, Novartis, Sensei, Tessa 	<ul style="list-style-type: none"> Not Specified, TBD
Munveer Bhangoo, MD (Scripps)	Speaker	<ul style="list-style-type: none"> Exelixis, BMS Foundation Medicine 	<ul style="list-style-type: none"> Speaker Consultant
Chris Chen, MD (Stanford)	Speaker	<ul style="list-style-type: none"> None 	<ul style="list-style-type: none"> N/A
Gregory Daniels, MD (UCSD)	Speaker	<ul style="list-style-type: none"> Sanofi, Regeneron Regeneron, Array BioPharma, Sanofi BMS, Amgen, Viralytics, Nektar, Merck 	<ul style="list-style-type: none"> Consultant Speakers Bureau Research Funding
George Fisher, MD (Stanford)	Speaker	<ul style="list-style-type: none"> Ipsen, Merck, Novartis Genentech, Ipsen, Jounce Therapeutics, Merck, Terumo, Taiho Pharmaceuticals 	<ul style="list-style-type: none"> Honoraria Consultant
Aaron Goodman, MD (UCSD)	Speaker	<ul style="list-style-type: none"> Seattle Genetics 	<ul style="list-style-type: none"> Speaker
Petros Grivas, MD (Fred Hutch)	Speaker	<ul style="list-style-type: none"> MSD, Bristol Myers Squibb, AstraZeneca, EMD Serono, Seagen, Pfizer, Janssen, Roche, Astellas Pharma, Gilead Sciences, Silverback Therapeutics, BostonGene, Fresenius Kabi, Lucence Health, PureTech, G1 Therapeutics, Aadi Biosciences, CG Oncology, Strata Oncology, ImmunityBio, Asieris Pharmaceuticals, AbbVie Pfizer, Bristol Myers Squibb, MSD, QED Therapeutics, GlaxoSmithKline, Mirati Therapeutics, EMD Serono, G1 Therapeutics, Gilead 	<ul style="list-style-type: none"> Consultant Research Funding

Scripps Cancer Center's Oncology Update 2024

July 20, 2024 • San Diego, CA

July 27, 2024 • Irvine, CA

August 3, 2024 • Seattle, WA

August 10, 2024 • Santa Clara, CA

		Sciences, Acrivon Therapeutics, ALX Oncology, Genentech	
Evan Hall, MD (Fred Hutch)	Speaker	<ul style="list-style-type: none"> Eisai Neoleukin Therapeutics, ImCheck Therapeutics, Nektar, Replimune, NiKang Therapeutics, Gilead, Pfizer 	<ul style="list-style-type: none"> Consultant Research Funding
Joel Hecht, MD (UCLA)	Speaker	<ul style="list-style-type: none"> Actym, ZelanBio, Rafael, Arum Astellas, Tempus, Gilead 	<ul style="list-style-type: none"> Stock Options Consultant
Joanne Mortimer, MD (City of Hope)	Speaker, Moderator	<ul style="list-style-type: none"> Novartis, GE Healthcare 	<ul style="list-style-type: none"> Consultant
Ronald Natale, MD (Cedars-Sinai)	Speaker	<ul style="list-style-type: none"> AstraZeneca, Blueprint Medicines, Johnson&Johnson, Merck, Millenium, Pfizer, Rgenix 	<ul style="list-style-type: none"> Research Funding
Kamya Sankar, MD (Cedars-Sinai)	Speaker	<ul style="list-style-type: none"> None 	<ul style="list-style-type: none"> N/A
Rafael Santana-Davila, MD (Fred Hutch)	Speaker	<ul style="list-style-type: none"> None 	<ul style="list-style-type: none"> N/A
Aditya Sarvaria, MD (Scripps)	Speaker	<ul style="list-style-type: none"> None 	<ul style="list-style-type: none"> N/A
Alan Saven, MD (Scripps)	Course Director, Moderator	<ul style="list-style-type: none"> BeiGene, Incyte, Pharmacyclics, Janssen, Eli Lilly, AbbVie 	<ul style="list-style-type: none"> Speaker
Darren Sigal, MD (Scripps)	Speaker	<ul style="list-style-type: none"> None 	<ul style="list-style-type: none"> N/A
Sandy Srinivas, MD (Stanford)	Speaker	<ul style="list-style-type: none"> Novartis, AVEO, Janssen Seagen REGN, Merck 	<ul style="list-style-type: none"> Advisory Board Advisory Board, Research Research
CME Committee	CE approval, all final decision-making on activities	<ul style="list-style-type: none"> None 	<ul style="list-style-type: none"> N/A
Scripps Conference Services & CME	Plan, manage, implement, and reconcile CE activities	<ul style="list-style-type: none"> None 	<ul style="list-style-type: none"> N/A

Glossary of Terms

Ineligible Company

An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. For specific examples of ineligible companies visit www.accme.org/standards.

Financial Relationships

Financial relationships include employee, researcher, consultant, advisor, speaker, independent contractor, research funding, royalties or patent beneficiary, executive role, and ownership interest. Individual stocks and stock options should be disclosed.

Scripps Cancer Center's Oncology Update 2024

July 20, 2024 • San Diego, CA
 July 27, 2024 • Irvine, CA
 August 3, 2024 • Seattle, WA
 August 10, 2024 • Santa Clara, CA